VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study
Titel:
VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study
Auteur:
Paz-Ares, L. O'Brien, M.E.R. Mauer, M. Dafni, U. Oselin, K. Havel, L. Esteban Gonzalez, E. Isla, D. Martinez-Marti, A. Faehling, M. Tsuboi, M. Lee, J-S. Nakagawa, K. Yang, J. Keller, S.M. Jha, N. Marreaud, S.I. Stahel, R.A. Peters, S. Besse, B.